Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Wajeeh Khan

As Hims & Hers Gets Hit With Major Wegovy Loss, Should You Buy the Dip in Deeply Oversold HIMS Stock?

Hims & Hers (HIMS) stock has crash more than 25% in recent sessions after Novo Nordisk (NVO) filed a sweeping patent-infringement lawsuit targeting the company’s semaglutide offerings. 

This legal punch follows a U.S. Food and Drug Administration (FDA) crackdown on unapproved GLP-1 compounding, forcing HIMS to abruptly abandon its new $49 oral Wegovy alternative. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.